MusthInsider

Latest On AnaptysBio, Inc (ANAB):

Updated on: March 19, 2021

Date/Time	Type	Description	Signal
2023-05-22 18:46 EST	News	AnaptysBio upgraded to neutral at JP Morgan on clinical execution	N/A
2023-05-21 00:00 EST	News	Stocks To Watch: Debt Ceiling Drama, Nvidia Earnings And Healthcare Conferences	N/A
2023-05-18 17:01 EST	News	AnaptysBio initiated Outperform at TD Cowen on anti-inflammatory agents	N/A
2023-05-12 06:14 EST	News	AnaptysBio GAAP EPS of -$1.58 misses by $0.53, revenue of $1.4M misses by $1.48M	N/A
2023-04-25 14:45 EST	News	GSK's Jemperli gets review in EU for expanded use in uterus cancer	N/A
2023-03-31 01:05 EST	News	AnaptysBio: Upside Could Be Lying Ahead Very Nicely	N/A
2023-03-01 22:46 EST	News	AnaptysBio GAAP EPS of -$0.93, revenue of $6.8M	N/A
2023-01-13 19:42 EST	News	AnaptysBio rises 10% on stock repurchase of up to $50M	N/A
2022-11-09 02:12 EST	News	AnaptysBio GAAP EPS of -$1.18 misses by $0.56, revenue of $1.29M misses by $12.14M	N/A
2022-11-01 22:23 EST	News	AnaptysBio raised to Buy at Guggenheim on prospects for checkpoint agonists	N/A
2022-10-05 18:17 EST	News	AnaptysBio benefits from results of GSK mid-stage Jemperli combo lung cancer trial	N/A
2022-09-14 00:51 EST	News	AnaptysBio cut to Hold at Truist citing high bar for hair loss treatment	N/A
2022-09-12 13:42 EST	News	AnaptysBio sells royalties from GSK-partnered Zejula for $45M	N/A
2022-09-01 01:51 EST	News	AnaptysBio skin condition candidate fails mid-stage trial; shares down 16%	N/A
2022-08-08 18:55 EST	News	AnaptysBio GAAP EPS of -$1.15 misses by $0.14, revenue of $1.21M misses by $4.4M	N/A
2022-05-04 22:42 EST	News	AnaptysBio GAAP EPS of -$1.31 misses by $0.32, revenue of $0.97M misses by $4.08M	N/A
2022-03-22 16:43 EST	News	AnaptysBio names interim CEO as Hamza Suria steps down	N/A
2022-03-22 16:42 EST	News	AnaptysBio cut to neutral at Guggenheim on future of pipeline	N/A
2022-03-14 23:38 EST	News	AnaptysBio acne treatment imsidolimab fails in mid-stage trial; shares down 12%	N/A
2021-11-05 01:02 EST	News	AnaptysBio EPS beats by $0.64, beats on revenue	N/A
2021-10-26 12:05 EST	News	AnaptysBio climbs 14%, will monetize portion of JEMPERLI royalties for $250M with Sagard	N/A
2021-10-04 23:16 EST	News	AnaptysBio reports updated data from imsidolimab mid-stage study in pustular psoriasis	N/A
2021-08-18 04:46 EST	News	AnaptysBio secures $20M milestone payment from GSK after JEMPERLI FDA approval	N/A
2021-08-18 04:46 EST	News	ANAB, TLRY, PFMT and BMRN among after hours movers	N/A
2021-08-09 22:59 EST	News	AnaptysBio EPS beats by $0.12, beats on revenue	N/A
2021-07-20 18:44 EST	News	AnaptysBio gains after report the company received a takeover offer	N/A
2021-05-05 11:31 EST	News	AnaptysBio EPS beats by $0.03, beats on revenue	N/A
2021-04-24 05:15 EST	News	AnaptysBio trades higher after FDA approval for Jemperli triggers $20M milestone payment	N/A
2021-04-24 05:14 EST	News	GlaxoSmithKline wins EU approval for Jemperli in endometrial cancer	N/A
2021-04-23 07:49 EST	News	AnaptysBio is trading higher after FDA approval for Jemperli in endometrial cancer (updated)	N/A
2021-03-17 12:05 EST	Analyst Rating	The Analyst Target Price has increased from $26.75 to $28.5.	Buy
2021-03-16 19:18 EST	News	AnaptysBio is set for a catalyst-rich phase after the recent selloff: Truist	N/A
2021-03-10 15:05 EST	Analyst Rating	The Analyst Target Price has decreased from $30.75 to $26.75.	Neutral
2021-03-09 03:06 EST	Analyst Rating	The Analyst Target Price has decreased from $33.25 to $30.75.	Neutral
2021-03-08 17:28 EST	News	AnaptysBio fails in mid-stage study for Imsidolimab in skin disease	N/A
2021-03-08 17:27 EST	News	AnaptysBio gets double downgrade at JPM after Imsidolimab trial failure	N/A
2021-03-03 02:39 EST	News	AnaptysBio: Upcoming Catalyst Seems Like Quite The Gamble	N/A
2021-03-01 15:05 EST	Analyst Rating	The Analyst Target Price has increased from $29.8 to $33.25.	Buy
2021-03-01 15:05 EST	Earnings Estimate	An EPS average of -$2.43 is estimated for the 2022 year.	Sell
2021-03-01 15:05 EST	Earnings Estimate	An EPS average of -$0.69 is estimated for the quarter ending on June 30, 2021.	Sell
2021-02-26 15:05 EST	Financials	Company financials have been released.	Neutral
2021-02-25 19:20 EST	News	AnaptysBio EPS beats by $0.15, beats on revenue	N/A
2021-02-12 11:05 EST	Analyst Rating	The Analyst Target Price has increased from $28 to $29.8.	Neutral
2021-02-11 20:59 EST	News	AnaptysBio rises after double-upgrade from JPM; positive risk/reward profile cited	N/A
2021-02-11 20:58 EST	News	AnaptysBio: Troubled History Of Drug Development	N/A
2020-12-13 03:11 EST	Financials	Company financials have been released.	Neutral
2020-12-01 10:36 EST	News	AnaptysBio: Imsidolimab Q4 FDA Meeting, Dostarlimab Q4 2020 Approval, And New Trial Initiations, 61% Upside	N/A
2020-11-18 06:57 EST	News	AnaptysBio (ANAB) Investor Presentation - Slideshow	N/A
2020-11-15 11:10 EST	Financials	Company financials have been released.	Neutral
2020-11-06 11:07 EST	Analyst Rating	The Analyst Target Price has increased from $27.5 to $28.	Neutral

About AnaptysBio, Inc (ANAB):

AnaptysBio, Inc., a clinical stage biotechnology company, engages in developing therapeutic product candidates for inflammation and immuno-oncology indications. The company's products include Imsidolimab, an IL-36R antibody that inhibits the interleukin-36 receptor for the treatment of various dermatological inflammatory diseases; ANB030, an anti-PD-1 agonist antibody program designed to augment PD-1 signaling through ANB030 treatment to suppress T-cell driven human inflammatory diseases; and ANB032, an anti-BTLA modulator antibody applicable to human inflammatory diseases associated with lymphoid and myeloid immune cell dysregulation. It also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. AnaptysBio, Inc. has a collaboration and license agreement with TESARO, Inc. and Celgene Corporation; and license agreements with United Kingdom Research and Innovation, as well as Millipore Corporation. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is headquartered in San Diego, California.

See Advanced Chart

General

Name AnaptysBio, Inc
Symbol ANAB
Type Common Stock
Exchange NASDAQ
Currency USD
Country USA
SectorHealthcare
IndustryBiotechnology
Full Time Employees 94
Fiscal Year EndDecember
IPO Date2017-01-26
Gic SectorHealth Care
Gic GroupPharmaceuticals, Biotechnology & Life Sciences
Gic IndustryBiotechnology
Gic SubIndustryBiotechnology
Web URLhttp://www.anaptysbio.com

Valuation

Price/Sales (Trailing 12 Mt.) 8.07
Price/Book (Most Recent Quarter) 1.53
Enterprise Value Revenue 2.85
Enterprise Value EBITDA 0.11

Financials

Most Recent Quarter 2020-12-31
Current Year EPS Estimate -$3.01
Next Year EPS Estimate -$3.09
Next Quarter EPS Estimate -$0.61
Profit Margin -27%
Operating Margin -32%
Return on Assets -4%
Return on Equity -5%
Revenue 75 million
Earnings Per Share -$3.01
Revenue Per Share $2.75
Gross Profit -5025000
Quarterly Earnings Growth 1900%

Highlights

Market Capitalization 587.28 million
EBITDA -87543000
PE Ratio -6.14
Analyst Target Price $28.5
Book Value Per Share $14.50

Share Statistics

Shares Outstanding 27.37 million
Shares Float 15.89 million
% Held by Insiders 77%
% Held by Institutions 106.22%
Shares Short 3.81 million
Shares Short Prior Month 3.74 million
Short Ratio 8.99
Short % of Float 21%
Short % of Shares Outstanding 14%

Technicals

Beta 0.13
52 Week High $35.86
52 Week Low $12.46
50 Day Moving Average 26.72
200 Day Moving Average 23.55

Dividends

Dividend Date N/A
ExDividend Date N/A
Dividend Yield 0%

AnaptysBio, Inc (ANAB) Dividend Calendar:

Ex-Dividend Date	Payment Date	Record Date	Declared Date	Amount

AnaptysBio, Inc (ANAB) Earnings History:

Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.

Quarter Date	Report Date	Actual Revenue	Reported EPS	EPS Estimate	Deviation from Estimate
2020-12-31	2021-02-25	$60 million	$1.20	$0.60	98.87%
2020-09-30	2020-11-04	$N/A	-$0.87	-$0.69	-26.45%
2020-06-30	2020-08-10	$N/A	-$0.79	-$0.65	-21.18%
2020-03-31	2020-05-06	$N/A	-$0.30	-$0.80	62.5%
2019-12-31	2020-03-02	$3 million	-$0.75	-$1.28	41.36%
2019-09-30	2019-11-08	$N/A	-$1.15	-$1.14	-0.46%
2019-06-30	2019-08-08	$5 million	-$0.89	-$0.95	6.66%
2019-03-31	2019-05-07	$N/A	-$0.82	-$0.78	-4.75%
2018-12-31	2019-02-28	$N/A	-$0.64	-$0.86	25.93%
2018-09-30	2018-11-08	$5 million	-$0.66	-$0.70	6.16%
2018-06-30	2018-08-07	$N/A	-$0.57	-$0.67	14.41%
2018-03-31	2018-05-08	$N/A	-$0.63	-$0.46	-36.22%
2017-12-31	2018-03-05	$3 million	-$0.30	-$0.42	28.37%
2017-09-30	2017-11-07	$-7000000	-$0.45	-$0.47	4.56%
2017-06-30	2017-08-10	$7 million	-$0.13	-$0.42	69.34%
2017-03-31	2017-05-11	$N/A	-$0.75	-$0.18	-310.96%
2016-12-31	2017-03-08	$2.75 million	-$0.19	-$0.10	-86.34%

AnaptysBio, Inc (ANAB) Company Financial Statements:

Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.

Income Statement:

Date
Research Development
Income Before Tax
Selling General Administrative
Gross Profit
Ebit
Operating Income
Income Tax Expense
Total Revenue
Cost of Revenue
Total Other Income Expense Net
Net Income From Continuing Operations
Net Income Applicable to Common Shares

Cash Flow:

Date
Investments
Change to Liabilities
Total Cash Flow from Investing Activities
Net Borrowings
Total Cash Flow from Financial Activities
Change to Operating Activities
Change in Cash
Total Cash from Operating Activities
Depreciation
Other Cash Flow from Investing Activities
Change to Inventory
Change to Account Receivables
Other Cash Flow from Financing Activities
Change to Net Income
Capital Expenditures

Balance Sheet:

Date
Total Liabailities
Total Stockholder Equity
Other Current Liabilities
Total Assets
Common Stock
Other Current Assets
Retained Earnings
Other Liabilities
Other Assets
Cash
Total Current Liabilities
Other Stockholder Equity
Property, Plant & Equipment
Total Current Assets
Long Term Investments
Net Tangible Assets
Short Term Investments
Long Term Debt
Inventory
Accounts Payable

AnaptysBio, Inc (ANAB) Chart:

AnaptysBio, Inc (ANAB) News:

Below you will find a list of latest news for AnaptysBio, Inc (ANAB) from major news sources. You can filter the results to only show news from a specific source.

No recent news available

AnaptysBio, Inc (ANAB) Options:

A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.

Expiration Date:

Options Type:

Moneyness:

Expiration Date	Strike	Last Price	Type	Volume	Open Interest	Implied Volatility	In The Money	Change	Change Percent
2026-01-16	12.5	10	CALL	0	2	0	TRUE	0	0
2026-01-16	15	35	CALL	0	6	0	TRUE	0	0
2026-01-16	17.5	7.67	CALL	0	51	0	TRUE	0	0
2026-01-16	20	28.12	CALL	0	7	0	TRUE	0	0
2026-01-16	22.5	14.29	CALL	0	0	0	TRUE	0	0
2026-01-16	25	23.17	CALL	0	10	180.63	TRUE	0	0
2026-01-16	30	13.85	CALL	0	1	0	TRUE	0	0
2026-01-16	35	12.56	CALL	0	10	101.24	TRUE	0	0
2026-01-16	40	4.65	CALL	0	79	89.64	TRUE	0	0
2026-01-16	45	2.13	CALL	3	31	99.45	FALSE	2.13	0
2026-01-16	50	0.45	CALL	0	34	301.47	FALSE	0	0
2026-01-16	55	0.85	CALL	0	2	363.27	FALSE	0	0
2026-01-16	60	0	CALL	0	0	414.33	FALSE	0	0
2026-01-16	12.5	0.15	PUT	0	45	851.17	FALSE	0	0
2026-01-16	15	0.65	PUT	0	2	936.72	FALSE	0	0
2026-01-16	17.5	1.91	PUT	0	6	1064.86	FALSE	0	0
2026-01-16	20	0.32	PUT	0	182	480.14	FALSE	0	0
2026-01-16	22.5	0.44	PUT	0	2	830.77	FALSE	0	0
2026-01-16	25	2.9	PUT	0	11	737.47	FALSE	0	0
2026-01-16	30	0.15	PUT	593	2709	181.46	FALSE	-0.15	-0.5
2026-01-16	35	0.25	PUT	0	2012	175.58	FALSE	0	0
2026-01-16	40	1.46	PUT	0	1	325.9	FALSE	0	0
2026-01-16	45	2.58	PUT	3	4	105.8	TRUE	2.58	0
2026-01-16	50	7.3	PUT	0	2	72.48	TRUE	0	0
2026-01-16	55	0	PUT	0	0	91.61	TRUE	0	0
2026-01-16	60	0	PUT	0	0	121.5	TRUE	0	0
2026-02-20	12.5	20.7	CALL	0	53	0	TRUE	0	0
2026-02-20	15	0	CALL	0	0	0	TRUE	0	0
2026-02-20	17.5	20.3	CALL	0	0	0	TRUE	0	0
2026-02-20	20	28	CALL	0	0	0	TRUE	0	0
2026-02-20	22.5	17.7	CALL	0	0	0	TRUE	0	0
2026-02-20	25	24.54	CALL	0	3	0	TRUE	0	0
2026-02-20	30	13.94	CALL	0	16	65.48	TRUE	0	0
2026-02-20	35	9.45	CALL	0	16	68.2	TRUE	0	0
2026-02-20	40	5.7	CALL	0	31	62.4	TRUE	0	0
2026-02-20	45	4.75	CALL	0	4002	61.89	FALSE	0	0
2026-02-20	50	2.15	CALL	0	30	114.38	FALSE	0	0
2026-02-20	55	1.2	CALL	8	16	69.37	FALSE	1.2	0
2026-02-20	60	0.15	CALL	0	5	113.76	FALSE	0	0
2026-02-20	65	0	CALL	0	0	174.51	FALSE	0	0
2026-02-20	70	0	CALL	0	0	189.21	FALSE	0	0
2026-02-20	12.5	0.1	PUT	0	12	545.23	FALSE	0	0
2026-02-20	15	3.28	PUT	0	6	468.11	FALSE	0	0
2026-02-20	17.5	1.55	PUT	0	1	408.54	FALSE	0	0
2026-02-20	20	0	PUT	0	0	359.98	FALSE	0	0
2026-02-20	22.5	4.85	PUT	0	0	318.9	FALSE	0	0
2026-02-20	25	5.27	PUT	0	0	283.19	FALSE	0	0
2026-02-20	30	4.4	PUT	0	5	222.75	FALSE	0	0
2026-02-20	35	0	PUT	0	0	171.71	FALSE	0	0
2026-02-20	40	1.45	PUT	0	0	125.8	FALSE	0	0
2026-02-20	45	2.46	PUT	0	2	65.99	TRUE	0	0
2026-02-20	50	3.98	PUT	0	2	57.01	TRUE	0	0
2026-02-20	55	0	PUT	0	0	58.31	TRUE	0	0
2026-02-20	60	0	PUT	0	0	53.08	TRUE	0	0
2026-02-20	65	0	PUT	0	0	64.32	TRUE	0	0
2026-02-20	70	0	PUT	0	0	78.35	TRUE	0	0
2026-05-15	2.5	0	CALL	0	0	0	TRUE	0	0
2026-05-15	5	0	CALL	0	0	0	TRUE	0	0
2026-05-15	7.5	0	CALL	0	0	0	TRUE	0	0
2026-05-15	10	0	CALL	0	0	133.25	TRUE	0	0
2026-05-15	12.5	0	CALL	0	0	110.09	TRUE	0	0
2026-05-15	15	23.5	CALL	0	1	91.09	TRUE	0	0
2026-05-15	17.5	0	CALL	0	0	81.47	TRUE	0	0
2026-05-15	20	0	CALL	0	0	67.42	TRUE	0	0
2026-05-15	22.5	0	CALL	0	0	82.8	TRUE	0	0
2026-05-15	25	0	CALL	0	0	69.12	TRUE	0	0
2026-05-15	30	19.3	CALL	0	58	73.64	TRUE	0	0
2026-05-15	35	12.5	CALL	9	14	67.59	TRUE	12.5	0
2026-05-15	40	10	CALL	3	8	73.11	TRUE	10	0
2026-05-15	45	6.8	CALL	0	2	62.21	FALSE	0	0
2026-05-15	50	4.27	CALL	0	4	61.1	FALSE	0	0
2026-05-15	55	4.76	CALL	0	23	59.72	FALSE	0	0
2026-05-15	60	0	CALL	0	0	89.3	FALSE	0	0
2026-05-15	65	0	CALL	0	0	98.97	FALSE	0	0
2026-05-15	70	0	CALL	0	0	107.44	FALSE	0	0
2026-05-15	2.5	0	PUT	0	0	0	FALSE	0	0
2026-05-15	5	0	PUT	0	0	969.98	FALSE	0	0
2026-05-15	7.5	0	PUT	0	0	483.18	FALSE	0	0
2026-05-15	10	0	PUT	0	0	376.87	FALSE	0	0
2026-05-15	12.5	0	PUT	0	0	314.12	FALSE	0	0
2026-05-15	15	0	PUT	0	0	199.42	FALSE	0	0
2026-05-15	17.5	1.9	PUT	0	0	235.54	FALSE	0	0
2026-05-15	20	3.35	PUT	0	10	207.66	FALSE	0	0
2026-05-15	22.5	0	PUT	0	0	184.08	FALSE	0	0
2026-05-15	25	5.4	PUT	0	1	163.6	FALSE	0	0
2026-05-15	30	2.62	PUT	0	8	128.96	FALSE	0	0
2026-05-15	35	3.19	PUT	0	1	99.74	FALSE	0	0
2026-05-15	40	2.61	PUT	0	3	66.45	FALSE	0	0
2026-05-15	45	6.3	PUT	8	0	61.53	TRUE	6.3	0
2026-05-15	50	0	PUT	0	0	60.96	TRUE	0	0
2026-05-15	55	0	PUT	0	0	59.75	TRUE	0	0
2026-05-15	60	0	PUT	0	0	59.96	TRUE	0	0
2026-05-15	65	0	PUT	0	0	60.15	TRUE	0	0
2026-05-15	70	0	PUT	0	0	62.79	TRUE	0	0
2026-08-21	22.5	0	CALL	0	0	72.87	TRUE	0	0
2026-08-21	25	27.1	CALL	0	10	69.63	TRUE	0	0
2026-08-21	30	20.8	CALL	0	6	67.69	TRUE	0	0
2026-08-21	35	0	CALL	0	0	65.44	TRUE	0	0
2026-08-21	40	0	CALL	0	0	65.03	TRUE	0	0
2026-08-21	45	11.62	CALL	0	1	63	FALSE	0	0
2026-08-21	50	7.5	CALL	0	35	66.76	FALSE	0	0
2026-08-21	55	0	CALL	0	0	61.79	FALSE	0	0
2026-08-21	60	4.5	CALL	0	5	62.04	FALSE	0	0
2026-08-21	65	0	CALL	0	0	62.16	FALSE	0	0
2026-08-21	70	0	CALL	0	0	79.65	FALSE	0	0
2026-08-21	22.5	0	PUT	0	0	139.03	FALSE	0	0
2026-08-21	25	0	PUT	0	0	123.67	FALSE	0	0
2026-08-21	30	0	PUT	0	0	70.16	FALSE	0	0
2026-08-21	35	0	PUT	0	0	71.34	FALSE	0	0
2026-08-21	40	0	PUT	0	0	64.82	FALSE	0	0
2026-08-21	45	0	PUT	0	0	63.36	TRUE	0	0
2026-08-21	50	0	PUT	0	0	58.55	TRUE	0	0
2026-08-21	55	0	PUT	0	0	58.17	TRUE	0	0
2026-08-21	60	0	PUT	0	0	59.83	TRUE	0	0
2026-08-21	65	0	PUT	0	0	58.62	TRUE	0	0
2026-08-21	70	0	PUT	0	0	57.36	TRUE	0	0

Latest ANAB Trades:

Date	Shares	Price
Jun 13, 2022 7:59 PM EST	8	$21.35
Jun 13, 2022 7:59 PM EST	1	$21.35
Jun 13, 2022 7:59 PM EST	200	$21.35
Jun 13, 2022 7:59 PM EST	54	$21.35
Jun 13, 2022 7:59 PM EST	13	$21.35

AnaptysBio, Inc (ANAB) SEC Filings:

An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.

Form Type:

Date	Form Type	Form Name	Link
2020-06-19	8-K	Current report	https://www.sec.gov/Archives/edgar/data/1370053/000137005320000039/0001370053-20-000039-index.htm
2018-09-11	UPLOAD	SEC-generated letter	https://www.sec.gov/Archives/edgar/data/1370053/000000000018028147/0000000000-18-028147-index.htm
2018-10-15	UPLOAD	SEC-generated letter	https://www.sec.gov/Archives/edgar/data/1370053/000000000018032332/0000000000-18-032332-index.htm
2020-02-13	SC 13G	Statement of acquisition of beneficial ownership by individuals	https://www.sec.gov/Archives/edgar/data/1370053/000009375120000338/0000093751-20-000338-index.htm
2019-02-04	SC 13G/A	Statement of acquisition of beneficial ownership by individuals	https://www.sec.gov/Archives/edgar/data/1370053/000021545719003201/0000215457-19-003201-index.htm
2019-02-13	SC 13G/A	Statement of acquisition of beneficial ownership by individuals	https://www.sec.gov/Archives/edgar/data/1370053/000031506619000857/0000315066-19-000857-index.htm
2019-12-10	SC 13G/A	Statement of acquisition of beneficial ownership by individuals	https://www.sec.gov/Archives/edgar/data/1370053/000031506619001800/0000315066-19-001800-index.htm
2020-02-05	SC 13G/A	Statement of acquisition of beneficial ownership by individuals	https://www.sec.gov/Archives/edgar/data/1370053/000083423720004777/0000834237-20-004777-index.htm
2019-02-13	SC 13G/A	Statement of acquisition of beneficial ownership by individuals	https://www.sec.gov/Archives/edgar/data/1370053/000090266419000927/0000902664-19-000927-index.htm
2020-02-12	SC 13G/A	Statement of acquisition of beneficial ownership by individuals	https://www.sec.gov/Archives/edgar/data/1370053/000090266420000965/0000902664-20-000965-index.htm
2020-02-04	SC 13G	Statement of acquisition of beneficial ownership by individuals	https://www.sec.gov/Archives/edgar/data/1370053/000092189520000234/0000921895-20-000234-index.htm
2019-02-14	SC 13G/A	Statement of acquisition of beneficial ownership by individuals	https://www.sec.gov/Archives/edgar/data/1370053/000092963819000269/0000929638-19-000269-index.htm
2019-02-11	SC 13G	Statement of acquisition of beneficial ownership by individuals	https://www.sec.gov/Archives/edgar/data/1370053/000093247119004736/0000932471-19-004736-index.htm
2019-11-18	SC 13G	Statement of acquisition of beneficial ownership by individuals	https://www.sec.gov/Archives/edgar/data/1370053/000093583619000611/0000935836-19-000611-index.htm
2020-02-14	SC 13G/A	Statement of acquisition of beneficial ownership by individuals	https://www.sec.gov/Archives/edgar/data/1370053/000093583620000141/0000935836-20-000141-index.htm
2018-05-15	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1370053/000101297518000436/0001012975-18-000436-index.htm
2018-05-15	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1370053/000101297518000437/0001012975-18-000437-index.htm
2018-05-15	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1370053/000101297518000438/0001012975-18-000438-index.htm
2018-05-15	SC 13D/A	General statement of acquisition of beneficial ownership	https://www.sec.gov/Archives/edgar/data/1370053/000107261318000346/0001072613-18-000346-index.htm
2020-02-12	SC 13G/A	Statement of acquisition of beneficial ownership by individuals	https://www.sec.gov/Archives/edgar/data/1370053/000110465920018330/0001104659-20-018330-index.htm
2018-03-20	8-K	Current report	https://www.sec.gov/Archives/edgar/data/1370053/000119312518089132/0001193125-18-089132-index.htm
2018-03-26	8-K	Current report	https://www.sec.gov/Archives/edgar/data/1370053/000119312518095907/0001193125-18-095907-index.htm
2018-09-24	8-K	Current report	https://www.sec.gov/Archives/edgar/data/1370053/000119312518280420/0001193125-18-280420-index.htm
2018-09-24	424B5	Prospectus [Rule 424(b)(5)]	https://www.sec.gov/Archives/edgar/data/1370053/000119312518281156/0001193125-18-281156-index.htm
2018-09-26	424B5	Prospectus [Rule 424(b)(5)]	https://www.sec.gov/Archives/edgar/data/1370053/000119312518283918/0001193125-18-283918-index.htm
2018-09-26	8-K	Current report	https://www.sec.gov/Archives/edgar/data/1370053/000119312518283933/0001193125-18-283933-index.htm
2019-02-14	SC 13D/A	General statement of acquisition of beneficial ownership	https://www.sec.gov/Archives/edgar/data/1370053/000119312519041203/0001193125-19-041203-index.htm
2020-08-20	8-K	Current report	https://www.sec.gov/Archives/edgar/data/1370053/000119312520225721/0001193125-20-225721-index.htm
2018-03-06	3	Initial statement of beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1370053/000120919118017376/0001209191-18-017376-index.htm
2018-03-06	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1370053/000120919118017377/0001209191-18-017377-index.htm
2018-04-18	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1370053/000120919118025382/0001209191-18-025382-index.htm
2018-06-11	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1370053/000120919118036984/0001209191-18-036984-index.htm
2018-07-11	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1370053/000120919118042363/0001209191-18-042363-index.htm
2018-08-08	3	Initial statement of beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1370053/000120919118045891/0001209191-18-045891-index.htm
2018-08-08	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1370053/000120919118045892/0001209191-18-045892-index.htm
2018-09-10	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1370053/000120919118050362/0001209191-18-050362-index.htm
2018-12-04	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1370053/000120919118061100/0001209191-18-061100-index.htm
2018-12-12	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1370053/000120919118062336/0001209191-18-062336-index.htm
2018-12-18	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1370053/000120919118063382/0001209191-18-063382-index.htm
2018-12-18	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1370053/000120919118063384/0001209191-18-063384-index.htm
2019-01-16	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1370053/000120919119003996/0001209191-19-003996-index.htm
2019-01-16	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1370053/000120919119003997/0001209191-19-003997-index.htm
2019-02-11	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1370053/000120919119009006/0001209191-19-009006-index.htm
2019-02-11	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1370053/000120919119009024/0001209191-19-009024-index.htm
2019-02-11	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1370053/000120919119009028/0001209191-19-009028-index.htm
2019-02-11	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1370053/000120919119009031/0001209191-19-009031-index.htm
2019-02-11	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1370053/000120919119009034/0001209191-19-009034-index.htm
2019-02-11	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1370053/000120919119009036/0001209191-19-009036-index.htm
2019-02-11	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1370053/000120919119009038/0001209191-19-009038-index.htm
2019-02-11	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1370053/000120919119009043/0001209191-19-009043-index.htm
2019-02-11	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1370053/000120919119009044/0001209191-19-009044-index.htm
2019-02-11	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1370053/000120919119009046/0001209191-19-009046-index.htm
2019-04-18	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1370053/000120919119025283/0001209191-19-025283-index.htm
2019-06-05	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1370053/000120919119034870/0001209191-19-034870-index.htm
2019-06-12	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1370053/000120919119036426/0001209191-19-036426-index.htm
2019-08-20	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1370053/000120919119046820/0001209191-19-046820-index.htm
2019-09-26	3	Initial statement of beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1370053/000120919119050888/0001209191-19-050888-index.htm
2019-09-26	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1370053/000120919119050889/0001209191-19-050889-index.htm
2019-11-25	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1370053/000120919119057952/0001209191-19-057952-index.htm
2019-12-02	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1370053/000120919119058549/0001209191-19-058549-index.htm
2019-12-10	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1370053/000120919119059923/0001209191-19-059923-index.htm
2019-12-10	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1370053/000120919119059924/0001209191-19-059924-index.htm
2019-12-17	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1370053/000120919119060981/0001209191-19-060981-index.htm
2020-02-06	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1370053/000120919120007246/0001209191-20-007246-index.htm
2020-02-06	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1370053/000120919120007251/0001209191-20-007251-index.htm
2020-02-13	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1370053/000120919120009309/0001209191-20-009309-index.htm
2020-02-13	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1370053/000120919120009316/0001209191-20-009316-index.htm
2020-02-13	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1370053/000120919120009322/0001209191-20-009322-index.htm
2020-02-13	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1370053/000120919120009325/0001209191-20-009325-index.htm
2020-02-13	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1370053/000120919120009327/0001209191-20-009327-index.htm
2020-02-13	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1370053/000120919120009329/0001209191-20-009329-index.htm
2020-03-10	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1370053/000120919120017742/0001209191-20-017742-index.htm
2020-07-15	3	Initial statement of beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1370053/000120919120042503/0001209191-20-042503-index.htm
2020-07-15	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1370053/000120919120042505/0001209191-20-042505-index.htm
2020-07-15	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1370053/000120919120042506/0001209191-20-042506-index.htm
2020-07-31	3	Initial statement of beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1370053/000120919120044257/0001209191-20-044257-index.htm
2020-07-31	4	Statement of changes in beneficial ownership of securities	https://www.sec.gov/Archives/edgar/data/1370053/000120919120044259/0001209191-20-044259-index.htm
2019-11-22	SC 13G	Statement of acquisition of beneficial ownership by individuals	https://www.sec.gov/Archives/edgar/data/1370053/000121465919007372/0001214659-19-007372-index.htm
2018-06-11	SC 13G/A	Statement of acquisition of beneficial ownership by individuals	https://www.sec.gov/Archives/edgar/data/1370053/000127417318000087/0001274173-18-000087-index.htm
2019-02-11	SC 13G/A	Statement of acquisition of beneficial ownership by individuals	https://www.sec.gov/Archives/edgar/data/1370053/000127417319000033/0001274173-19-000033-index.htm
2019-12-10	SC 13G/A	Statement of acquisition of beneficial ownership by individuals	https://www.sec.gov/Archives/edgar/data/1370053/000127417319000125/0001274173-19-000125-index.htm
2019-08-19	SC 13G	Statement of acquisition of beneficial ownership by individuals	https://www.sec.gov/Archives/edgar/data/1370053/000131924419000074/0001319244-19-000074-index.htm
2020-01-27	SC 13G/A	Statement of acquisition of beneficial ownership by individuals	https://www.sec.gov/Archives/edgar/data/1370053/000131924420000020/0001319244-20-000020-index.htm
2018-04-26	DEF 14A	Other definitive proxy statements	https://www.sec.gov/Archives/edgar/data/1370053/000137005318000020/0001370053-18-000020-index.htm
2018-04-26	DEFA14A	Additional definitive proxy soliciting materials and Rule 14(a)(12) material	https://www.sec.gov/Archives/edgar/data/1370053/000137005318000022/0001370053-18-000022-index.htm
2018-05-08	8-K	Current report	https://www.sec.gov/Archives/edgar/data/1370053/000137005318000026/0001370053-18-000026-index.htm
2018-05-08	10-Q	Quarterly report [Sections 13 or 15(d)]	https://www.sec.gov/Archives/edgar/data/1370053/000137005318000027/0001370053-18-000027-index.htm
2018-05-23	8-K	Current report	https://www.sec.gov/Archives/edgar/data/1370053/000137005318000029/0001370053-18-000029-index.htm
2018-06-12	8-K	Current report	https://www.sec.gov/Archives/edgar/data/1370053/000137005318000031/0001370053-18-000031-index.htm
2018-08-07	8-K	Current report	https://www.sec.gov/Archives/edgar/data/1370053/000137005318000036/0001370053-18-000036-index.htm
2018-08-07	10-Q	Quarterly report [Sections 13 or 15(d)]	https://www.sec.gov/Archives/edgar/data/1370053/000137005318000037/0001370053-18-000037-index.htm
2018-09-14	10-K/A	Annual report [Section 13 and 15(d), not S-K Item 405]	https://www.sec.gov/Archives/edgar/data/1370053/000137005318000041/0001370053-18-000041-index.htm
2018-09-14	10-Q/A	Quarterly report [Sections 13 or 15(d)]	https://www.sec.gov/Archives/edgar/data/1370053/000137005318000042/0001370053-18-000042-index.htm
2018-09-14	10-Q/A	Quarterly report [Sections 13 or 15(d)]	https://www.sec.gov/Archives/edgar/data/1370053/000137005318000043/0001370053-18-000043-index.htm
2018-09-19	CORRESP	Correspondence	https://www.sec.gov/Archives/edgar/data/1370053/000137005318000046/0001370053-18-000046-index.htm
2018-11-08	8-K	Current report	https://www.sec.gov/Archives/edgar/data/1370053/000137005318000051/0001370053-18-000051-index.htm
2018-11-08	10-Q	Quarterly report [Sections 13 or 15(d)]	https://www.sec.gov/Archives/edgar/data/1370053/000137005318000052/0001370053-18-000052-index.htm
2019-02-28	8-K	Current report	https://www.sec.gov/Archives/edgar/data/1370053/000137005319000004/0001370053-19-000004-index.htm
2019-02-28	10-K	Annual report [Section 13 and 15(d), not S-K Item 405]	https://www.sec.gov/Archives/edgar/data/1370053/000137005319000006/0001370053-19-000006-index.htm
2019-02-28	S-8	Securities to be offered to employees in employee benefit plans	https://www.sec.gov/Archives/edgar/data/1370053/000137005319000007/0001370053-19-000007-index.htm
2019-04-26	DEF 14A	Other definitive proxy statements	https://www.sec.gov/Archives/edgar/data/1370053/000137005319000013/0001370053-19-000013-index.htm
2019-04-26	DEFA14A	Additional definitive proxy soliciting materials and Rule 14(a)(12) material	https://www.sec.gov/Archives/edgar/data/1370053/000137005319000014/0001370053-19-000014-index.htm
2019-05-07	8-K	Current report	https://www.sec.gov/Archives/edgar/data/1370053/000137005319000018/0001370053-19-000018-index.htm
2019-05-07	10-Q	Quarterly report [Sections 13 or 15(d)]	https://www.sec.gov/Archives/edgar/data/1370053/000137005319000019/0001370053-19-000019-index.htm
2019-06-11	8-K	Current report	https://www.sec.gov/Archives/edgar/data/1370053/000137005319000021/0001370053-19-000021-index.htm
2019-08-08	8-K	Current report	https://www.sec.gov/Archives/edgar/data/1370053/000137005319000026/0001370053-19-000026-index.htm
2019-08-08	10-Q	Quarterly report [Sections 13 or 15(d)]	https://www.sec.gov/Archives/edgar/data/1370053/000137005319000027/0001370053-19-000027-index.htm
2019-08-19	8-K	Current report	https://www.sec.gov/Archives/edgar/data/1370053/000137005319000029/0001370053-19-000029-index.htm
2019-09-25	8-K	Current report	https://www.sec.gov/Archives/edgar/data/1370053/000137005319000031/0001370053-19-000031-index.htm
2019-09-30	8-K	Current report	https://www.sec.gov/Archives/edgar/data/1370053/000137005319000035/0001370053-19-000035-index.htm
2019-11-08	8-K	Current report	https://www.sec.gov/Archives/edgar/data/1370053/000137005319000041/0001370053-19-000041-index.htm
2019-11-08	10-Q	Quarterly report [Sections 13 or 15(d)]	https://www.sec.gov/Archives/edgar/data/1370053/000137005319000042/0001370053-19-000042-index.htm
2020-01-15	8-K	Current report	https://www.sec.gov/Archives/edgar/data/1370053/000137005320000003/0001370053-20-000003-index.htm
2020-03-02	8-K	Current report	https://www.sec.gov/Archives/edgar/data/1370053/000137005320000007/0001370053-20-000007-index.htm
2020-03-02	10-K	Annual report [Section 13 and 15(d), not S-K Item 405]	https://www.sec.gov/Archives/edgar/data/1370053/000137005320000009/0001370053-20-000009-index.htm
2020-03-02	S-8	Securities to be offered to employees in employee benefit plans	https://www.sec.gov/Archives/edgar/data/1370053/000137005320000010/0001370053-20-000010-index.htm
2020-03-09	8-K	Current report	https://www.sec.gov/Archives/edgar/data/1370053/000137005320000013/0001370053-20-000013-index.htm
2020-04-27	DEF 14A	Other definitive proxy statements	https://www.sec.gov/Archives/edgar/data/1370053/000137005320000019/0001370053-20-000019-index.htm
2020-04-27	DEFA14A	Additional definitive proxy soliciting materials and Rule 14(a)(12) material	https://www.sec.gov/Archives/edgar/data/1370053/000137005320000020/0001370053-20-000020-index.htm
2020-05-06	8-K	Current report	https://www.sec.gov/Archives/edgar/data/1370053/000137005320000025/0001370053-20-000025-index.htm
2020-05-06	10-Q	Quarterly report [Sections 13 or 15(d)]	https://www.sec.gov/Archives/edgar/data/1370053/000137005320000026/0001370053-20-000026-index.htm
2020-06-19	8-K	Current report	https://www.sec.gov/Archives/edgar/data/1370053/000137005320000039/0001370053-20-000039-index.htm
2020-07-15	8-K	Current report	https://www.sec.gov/Archives/edgar/data/1370053/000137005320000042/0001370053-20-000042-index.htm
2020-07-31	8-K	Current report	https://www.sec.gov/Archives/edgar/data/1370053/000137005320000045/0001370053-20-000045-index.htm
2020-08-10	8-K	Current report	https://www.sec.gov/Archives/edgar/data/1370053/000137005320000050/0001370053-20-000050-index.htm
2020-08-10	10-Q	Quarterly report [Sections 13 or 15(d)]	https://www.sec.gov/Archives/edgar/data/1370053/000137005320000051/0001370053-20-000051-index.htm
2020-10-13	8-K	Current report	https://www.sec.gov/Archives/edgar/data/1370053/000137005320000053/0001370053-20-000053-index.htm
2020-10-26	8-K	Current report	https://www.sec.gov/Archives/edgar/data/1370053/000137005320000057/0001370053-20-000057-index.htm
2020-11-04	8-K	Current report	https://www.sec.gov/Archives/edgar/data/1370053/000137005320000064/0001370053-20-000064-index.htm
2020-11-04	10-Q	Quarterly report [Sections 13 or 15(d)]	https://www.sec.gov/Archives/edgar/data/1370053/000137005320000065/0001370053-20-000065-index.htm
2020-02-13	SC 13G	Statement of acquisition of beneficial ownership by individuals	https://www.sec.gov/Archives/edgar/data/1370053/000162363220000230/0001623632-20-000230-index.htm
2020-04-09	SC 13G/A	Statement of acquisition of beneficial ownership by individuals	https://www.sec.gov/Archives/edgar/data/1370053/000162363220000855/0001623632-20-000855-index.htm

AnaptysBio, Inc (ANAB) Insider Transactions:

Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of AnaptysBio, Inc (ANAB). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.
Insider Ownership: 77%
Institutional Ownership: 10622%

Transaction Date	Insider Name	Insider Title	Type	Shares Number	Shares Price	Total Transaction	Shares Held After Transaction	Link
2018-12-03	Dominic Piscitelli	Chief Financial Officer	Sell	1,100.00	75.81	83,390.01	0.00	https://www.sec.gov/Archives/edgar/data/1370053/000120919118061100/0001209191-18-061100-index.htm
2018-12-03	Dominic Piscitelli	Chief Financial Officer	Sell	4,820.00	72.24	348,212.22	10,022.00	https://www.sec.gov/Archives/edgar/data/1370053/000120919118061100/0001209191-18-061100-index.htm
2018-12-03	Dominic Piscitelli	Chief Financial Officer	Sell	6,624.00	74.33	492,361.92	1,100.00	https://www.sec.gov/Archives/edgar/data/1370053/000120919118061100/0001209191-18-061100-index.htm
2018-09-07	Marco Londei	Chief Medical Officer	Buy	142,857.00	0.70	99,999.90	144,877.00	https://www.sec.gov/Archives/edgar/data/1370053/000120919118050362/0001209191-18-050362-index.htm
2018-12-17	Marco Londei	Chief Medical Officer	Sell	6,741.00	68.47	461,577.84	144,877.00	https://www.sec.gov/Archives/edgar/data/1370053/000120919118063384/0001209191-18-063384-index.htm
2018-12-03	Dominic Piscitelli	Chief Financial Officer	Sell	18,604.00	71.33	1,327,060.53	14,842.00	https://www.sec.gov/Archives/edgar/data/1370053/000120919118061100/0001209191-18-061100-index.htm
2018-12-17	Marco Londei	Chief Medical Officer	Sell	8,002.00	67.57	540,683.94	151,618.00	https://www.sec.gov/Archives/edgar/data/1370053/000120919118063384/0001209191-18-063384-index.htm
2018-12-17	Marco Londei	Chief Medical Officer	Buy	8,048.00	0.70	5,633.60	152,925.00	https://www.sec.gov/Archives/edgar/data/1370053/000120919118063384/0001209191-18-063384-index.htm
2018-12-17	Marco Londei	Chief Medical Officer	Sell	3,185.00	66.38	211,416.16	159,620.00	https://www.sec.gov/Archives/edgar/data/1370053/000120919118063384/0001209191-18-063384-index.htm
2018-12-17	Marco Londei	Chief Medical Officer	Sell	12,120.00	65.36	792,177.74	162,805.00	https://www.sec.gov/Archives/edgar/data/1370053/000120919118063384/0001209191-18-063384-index.htm
2018-12-17	Marco Londei	Chief Medical Officer	Buy	22,000.00	6.93	152,460.00	174,925.00	https://www.sec.gov/Archives/edgar/data/1370053/000120919118063384/0001209191-18-063384-index.htm
2019-06-10	Hamza Suria	President, CEO	Sell	454.00	76.31	34,644.74	17,636.00	https://www.sec.gov/Archives/edgar/data/1370053/000120919119036426/0001209191-19-036426-index.htm
2019-06-10	Hamza Suria	President, CEO	Sell	1,994.00	75.86	151,270.82	18,090.00	https://www.sec.gov/Archives/edgar/data/1370053/000120919119036426/0001209191-19-036426-index.htm
2019-06-10	Hamza Suria	President, CEO	Sell	5,000.00	74.68	373,412.50	20,084.00	https://www.sec.gov/Archives/edgar/data/1370053/000120919119036426/0001209191-19-036426-index.htm
2019-01-15	Marco Londei	Chief Medical Officer	Sell	14,894.00	70.04	1,043,195.12	22,377.00	https://www.sec.gov/Archives/edgar/data/1370053/000120919119003996/0001209191-19-003996-index.htm
2019-06-04	Marco Londei	Chief Medical Officer	Sell	2,003.00	74.50	149,219.09	22,377.00	https://www.sec.gov/Archives/edgar/data/1370053/000120919119034870/0001209191-19-034870-index.htm
2019-06-04	Marco Londei	Chief Medical Officer	Sell	2,048.00	73.43	150,383.82	24,380.00	https://www.sec.gov/Archives/edgar/data/1370053/000120919119034870/0001209191-19-034870-index.htm
2019-06-10	Hamza Suria	President, CEO	Sell	6,440.00	73.70	474,637.02	25,084.00	https://www.sec.gov/Archives/edgar/data/1370053/000120919119036426/0001209191-19-036426-index.htm
2019-06-04	Marco Londei	Chief Medical Officer	Sell	6,009.00	72.45	435,358.66	26,428.00	https://www.sec.gov/Archives/edgar/data/1370053/000120919119034870/0001209191-19-034870-index.htm
2018-04-16	Nicholas Lydon	Director	Sell	2,222.00	90.26	200,549.05	271,106.00	https://www.sec.gov/Archives/edgar/data/1370053/000120919118025382/0001209191-18-025382-index.htm
2018-04-16	Nicholas Lydon	Director	Sell	2,803.00	89.42	250,631.37	273,328.00	https://www.sec.gov/Archives/edgar/data/1370053/000120919118025382/0001209191-18-025382-index.htm
2018-06-08	Hamza Suria	President, CEO	Buy	22,428.00	2.59	58,088.52	27,426.00	https://www.sec.gov/Archives/edgar/data/1370053/000120919118036984/0001209191-18-036984-index.htm
2018-04-16	Nicholas Lydon	Director	Sell	4,250.00	88.30	375,267.35	276,131.00	https://www.sec.gov/Archives/edgar/data/1370053/000120919118025382/0001209191-18-025382-index.htm
2019-11-22	Hamza Suria	President, CEO	Buy	10,000.00	1.12	11,200.00	27,636.00	https://www.sec.gov/Archives/edgar/data/1370053/000120919119057952/0001209191-19-057952-index.htm
2018-04-16	Nicholas Lydon	Director	Sell	9,425.00	87.46	824,340.66	280,381.00	https://www.sec.gov/Archives/edgar/data/1370053/000120919118025382/0001209191-18-025382-index.htm
2018-07-09	Hamza Suria	President, CEO	Buy	1,428.00	2.24	3,198.72	28,854.00	https://www.sec.gov/Archives/edgar/data/1370053/000120919118042363/0001209191-18-042363-index.htm
2018-04-16	Nicholas Lydon	Director	Sell	1,390.00	86.15	119,752.95	289,806.00	https://www.sec.gov/Archives/edgar/data/1370053/000120919118025382/0001209191-18-025382-index.htm
2018-04-16	Nicholas Lydon	Director	Sell	10,310.00	85.11	877,491.32	291,196.00	https://www.sec.gov/Archives/edgar/data/1370053/000120919118025382/0001209191-18-025382-index.htm
2018-12-11	Hamza Suria	President, CEO	Sell	4,998.00	70.83	354,008.34	30,064.00	https://www.sec.gov/Archives/edgar/data/1370053/000120919118062336/0001209191-18-062336-index.htm
2018-12-12	Hamza Suria	President, CEO	Sell	8,324.00	72.88	606,618.16	30,064.00	https://www.sec.gov/Archives/edgar/data/1370053/000120919118062336/0001209191-18-062336-index.htm
2018-12-14	Hamza Suria	President, CEO	Sell	7,800.00	70.51	549,978.78	30,064.00	https://www.sec.gov/Archives/edgar/data/1370053/000120919118063382/0001209191-18-063382-index.htm
2019-01-14	Hamza Suria	President, CEO	Sell	12,240.00	71.10	870,304.39	30,064.00	https://www.sec.gov/Archives/edgar/data/1370053/000120919119003997/0001209191-19-003997-index.htm
2018-04-16	Nicholas Lydon	Director	Sell	2,600.00	84.18	218,879.96	301,506.00	https://www.sec.gov/Archives/edgar/data/1370053/000120919118025382/0001209191-18-025382-index.htm
2019-06-10	Hamza Suria	President, CEO	Sell	8,540.00	72.64	620,384.88	31,524.00	https://www.sec.gov/Archives/edgar/data/1370053/000120919119036426/0001209191-19-036426-index.htm
2019-06-04	Marco Londei	Chief Medical Officer	Buy	10,060.00	0.70	7,042.00	32,437.00	https://www.sec.gov/Archives/edgar/data/1370053/000120919119034870/0001209191-19-034870-index.htm
2018-12-03	Dominic Piscitelli	Chief Financial Officer	Sell	3,554.00	70.34	249,974.14	33,446.00	https://www.sec.gov/Archives/edgar/data/1370053/000120919118061100/0001209191-18-061100-index.htm
2018-07-09	Hamza Suria	President, CEO	Buy	6,208.00	1.61	9,994.88	35,062.00	https://www.sec.gov/Archives/edgar/data/1370053/000120919118042363/0001209191-18-042363-index.htm
2018-12-10	Hamza Suria	President, CEO	Sell	4,964.00	72.48	359,805.12	35,062.00	https://www.sec.gov/Archives/edgar/data/1370053/000120919118062336/0001209191-18-062336-index.htm
2019-12-10	J. Anthony Ware	Director	Buy	3,600.00	14.05	50,580.00	3,600.00	https://www.sec.gov/Archives/edgar/data/1370053/000120919120007251/0001209191-20-007251-index.htm
2018-12-03	Dominic Piscitelli	Chief Financial Officer	Buy	37,000.00	11.34	419,580.00	37,000.00	https://www.sec.gov/Archives/edgar/data/1370053/000120919118061100/0001209191-18-061100-index.htm
2019-01-15	Marco Londei	Chief Medical Officer	Sell	4,181.00	69.29	289,686.44	37,271.00	https://www.sec.gov/Archives/edgar/data/1370053/000120919119003996/0001209191-19-003996-index.htm
2020-02-05	Hamza Suria	President, CEO	Buy	10,000.00	1.12	11,200.00	37,636.00	https://www.sec.gov/Archives/edgar/data/1370053/000120919120007246/0001209191-20-007246-index.htm
2018-12-14	Hamza Suria	President, CEO	Sell	9,084.00	69.68	632,967.67	37,864.00	https://www.sec.gov/Archives/edgar/data/1370053/000120919118063382/0001209191-18-063382-index.htm
2018-12-12	Hamza Suria	President, CEO	Sell	9,673.00	71.92	695,717.95	38,388.00	https://www.sec.gov/Archives/edgar/data/1370053/000120919118062336/0001209191-18-062336-index.htm
2018-12-10	Hamza Suria	President, CEO	Sell	10,347.00	71.49	739,700.82	40,026.00	https://www.sec.gov/Archives/edgar/data/1370053/000120919118062336/0001209191-18-062336-index.htm
2019-04-17	Hamza Suria	President, CEO	Buy	10,000.00	1.12	11,200.00	40,064.00	https://www.sec.gov/Archives/edgar/data/1370053/000120919119025283/0001209191-19-025283-index.htm
2019-01-15	Marco Londei	Chief Medical Officer	Buy	19,075.00	6.93	132,189.75	41,452.00	https://www.sec.gov/Archives/edgar/data/1370053/000120919119003996/0001209191-19-003996-index.htm
2019-01-14	Hamza Suria	President, CEO	Sell	27,760.00	70.65	1,961,227.34	42,304.00	https://www.sec.gov/Archives/edgar/data/1370053/000120919119003997/0001209191-19-003997-index.htm
2018-12-14	Hamza Suria	President, CEO	Sell	24,844.00	68.89	1,711,428.63	46,948.00	https://www.sec.gov/Archives/edgar/data/1370053/000120919118063382/0001209191-18-063382-index.htm
2020-03-10	Hamza Suria	President, CEO	Buy	10,000.00	1.12	11,200.00	47,636.00	https://www.sec.gov/Archives/edgar/data/1370053/000120919120017742/0001209191-20-017742-index.htm
2018-12-12	Hamza Suria	President, CEO	Sell	12,003.00	71.11	853,480.52	48,061.00	https://www.sec.gov/Archives/edgar/data/1370053/000120919118062336/0001209191-18-062336-index.htm
2018-12-10	Hamza Suria	President, CEO	Sell	15,276.00	70.57	1,078,082.31	50,373.00	https://www.sec.gov/Archives/edgar/data/1370053/000120919118062336/0001209191-18-062336-index.htm
2018-12-12	Hamza Suria	President, CEO	Buy	30,000.00	1.12	33,600.00	60,064.00	https://www.sec.gov/Archives/edgar/data/1370053/000120919118062336/0001209191-18-062336-index.htm
2018-12-10	Hamza Suria	President, CEO	Buy	30,587.00	1.12	34,257.44	65,649.00	https://www.sec.gov/Archives/edgar/data/1370053/000120919118062336/0001209191-18-062336-index.htm
2019-11-27	Marco Londei	Chief Medical Officer	Buy	46,202.00	6.93	320,179.86	68,579.00	https://www.sec.gov/Archives/edgar/data/1370053/000120919119058549/0001209191-19-058549-index.htm
2019-01-14	Hamza Suria	President, CEO	Buy	40,000.00	1.12	44,800.00	70,064.00	https://www.sec.gov/Archives/edgar/data/1370053/000120919119003997/0001209191-19-003997-index.htm
2018-12-14	Hamza Suria	President, CEO	Buy	41,728.00	1.12	46,735.36	71,792.00	https://www.sec.gov/Archives/edgar/data/1370053/000120919118063382/0001209191-18-063382-index.htm
2018-12-03	Dominic Piscitelli	Chief Financial Officer	Sell	2,298.00	73.18	168,158.68	7,724.00	https://www.sec.gov/Archives/edgar/data/1370053/000120919118061100/0001209191-18-061100-index.htm

AnaptysBio, Inc

(NASDAQ:ANAB)